Recently, a novel treatment response evaluation framework, factoring in PSMA-positive tumor volume and new lesions on PSMA-PET/CT (RECIP 1.0) as well as a composite classification, also taking into account biochemical response (RECIP + PSA), were developed and retrospectively validated in patients with mCRPC who had been treated with two cycles of [177Lu]Lu-PSMA RLT [12]. The gene discussed is FOLH1; the disease is neoplasm.